Related Experiment Video
Updated: May 21, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
A Glutathione-Responsive System with Prodrug and Sensitization Strategies for Targeted Therapy of Glioma
Xifeng Zhang1, Bilan Wang2, Xin Qi1
1Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, P. R. China.
Abstract:
Glioblastoma represents a highly aggressive form of malignant tumor within the central nervous system. Although chemotherapy remains the primary therapeutic strategy, its efficacy is often limited. To overcome the limitations associated with chemotherapeutic agents, such as high toxicity and non-specific adverse effects, a novel nanoparticle system comprising cRGD-modified and glutathione (GSH)-responsive polymers, and PEG-ss-Dox and apatinib (AP) (PDOX-AP/cRGD-NPs) is developed. PDOX-AP/cRGD-NPs show effective penetration of the blood-brain barrier (BBB), facilitate targeted delivery to brain tumors, and exhibit controlled drug release. PDOX-AP/cRGD-NPs show more effect in reducing the viability of GL-261, U87-MG, and LN-229 cells, inhibiting clonogenicity, and suppressing anti-apoptotic protein expression than PDOX/cRGD-NPs or AP/cRGD-NPs. Additionally, PDOX-AP/cRGD-NPs substantially increase drug uptake, BBB penetration, apoptosis rates, and the proportion of cells in the G2 phase. In vivo experiments further reveal that cRGD-directed nanoparticles exhibit superior accumulation in glioma regions compared to their non-cRGD-modified counterparts. In the interim, PDOX-AP/cRGD-NPs demonstrate significant efficacy in suppressing both ectopic and orthotopic growth of GL-261 gliomas, as well as orthotopic LN-229 gliomas, thereby markedly extending the median survival duration. This study introduces a promising targeted co-delivery system for combination chemotherapy.
Insights
A novel nanoparticle system effectively targets glioblastoma by crossing the blood-brain barrier and delivering chemotherapy. This targeted approach enhances drug delivery and significantly improves survival rates in preclinical models.
Area of Science:
- Nanomedicine
- Oncology
- Biotechnology
Background:
- Glioblastoma is an aggressive brain tumor with limited chemotherapy efficacy.
- Current treatments face challenges like high toxicity and non-specific side effects.
- Novel drug delivery systems are needed to improve glioblastoma treatment outcomes.
Purpose of the Study:
- To develop and evaluate a novel nanoparticle system for targeted glioblastoma chemotherapy.
- To assess the efficacy of cRGD-modified and GSH-responsive nanoparticles co-delivering Doxorubicin and Apatinib (PDOX-AP/cRGD-NPs).
- To investigate the system's ability to penetrate the blood-brain barrier (BBB) and target brain tumors.
Main Methods:
- Development of cRGD-modified, GSH-responsive nanoparticles (PDOX-AP/cRGD-NPs) co-delivering Doxorubicin (Dox) and Apatinib (AP).
- In vitro evaluation of cytotoxicity, clonogenicity, and apoptosis in glioblastoma cell lines (GL-261, U87-MG, LN-229).
- In vivo studies assessing BBB penetration, tumor accumulation, tumor growth inhibition, and survival in glioma models.
Main Results:
- PDOX-AP/cRGD-NPs demonstrated enhanced BBB penetration and targeted delivery to brain tumors.
- The nanoparticles significantly reduced glioblastoma cell viability, clonogenicity, and anti-apoptotic protein expression.
- In vivo studies showed superior glioma targeting, suppressed tumor growth, and extended median survival duration.
Conclusions:
- The developed PDOX-AP/cRGD-NPs represent a promising targeted co-delivery system for glioblastoma combination chemotherapy.
- This nanoparticle system overcomes limitations of traditional chemotherapy by improving drug delivery and efficacy.
- The findings support the potential of this novel nanomedicine for treating aggressive brain tumors.
